Avai Bio (AVAI) Equity Average (2018 - 2025)

Avai Bio has disclosed Equity Average across 8 years of filings, most recently posting -$2.5 million for Q4 2025.

• Equity Average for Q4 2025 came in at -$2.5 million, down 228.96% year-over-year; the trailing twelve-month figure through Dec 2025 was -$2.5 million (down 228.96% YoY), and the FY2025 annual result was -$1.5 million, down 44.32% from the prior year.
• Equity Average came in at -$2.5 million for Q4 2025 at Avai Bio, down from -$2.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $2.0 million in Q4 2024 to a low of -$2.5 million in Q4 2025.
• The 5-year median for Equity Average is -$454787.2 (2022), against an average of -$679389.0.
• Across the five-year window, Equity Average slumped 69498.06% in 2022 and jumped 265.17% in 2024, its largest moves.
• Avai Bio's Equity Average stood at -$241481.0 in 2021, then slumped by 98.63% to -$479653.5 in 2022, then slumped by 149.37% to -$1.2 million in 2023, then surged by 265.17% to $2.0 million in 2024, then sank by 228.96% to -$2.5 million in 2025.
• The last three Equity Average figures came in at -$2.5 million (Q4 2025), -$2.1 million (Q3 2025), and -$1.8 million (Q2 2025), per Business Quant data.